Last updated on August 2017

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis


Brief description of study

This is a dose escalation study to test the safety, tolerability and preliminary efficacy of ASN002 in people with moderate to severe atopic dermatitis (AD).

Detailed Study Description

This study is a dose escalation study to determine a safe and tolerable dose of ASN002 for people with moderate to severe atopic dermatitis. This study will also characterize the pharmacokinetics and pharmacodynamics of ASN002 through blood sampling and skin biopsies. Subjects will also be assessed for improvement in their atopic dermatitis. There will be a screening period (up to 30 days) and a treatment period for 4 weeks with a 14 day follow up with an end-of-study visit.

Clinical Study Identifier: NCT03139981

Contact Investigators or Research Sites near you

Start Over

Sunil Dhawan, MD

Center for Dermatology Clinical Research, Inc.
Fremont, CA United States
  Connect »

Howard Sofen, MD

Dermatology Research Associates
Los Angeles, CA United States
  Connect »

Neal Bhatia, MD

TCR Medical Corporation
San Diego, CA United States
  Connect »

Matthew Zook, MD

Olympian Clinical Research
Tampa, FL United States
  Connect »

Seth Forman, MD

Forward Clinical Trials, Inc.
Tampa, FL United States
  Connect »

Joseph Fowler, MD

Dermatology Specialists Research
Louisville, KY United States
  Connect »

Stephen Tyring, MD

Center for Clinical Studies, Ltd., LLP
Houston, TX United States
  Connect »

Mark Lee, MD

Progressive Clinical Research, P.A.
San Antonio, TX United States
  Connect »

David Pariser, MD

Virginia Clinical Research, Inc.
Norfolk, VA United States
  Connect »

Catherine Maari, MD

Innovaderm Research
Montréal, Canada
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.